NCT03400176 - VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

VAY736

Experimental

DRUG

ibrutinib

Approved medication

Trial Locations (5)

SCRI Oncology Partners, Nashville

Ohio ST Compr Cancer Ctr James Hosp, Columbus

Uni of Utah Huntsman Cancer Inst, Salt Lake City

David Geffen School of Medicine at UCLA, Los Angeles

University of California San Diego - Moores Cancer Center, La Jolla